Literature DB >> 15150731

Pharmacokinetics and lung tissue concentrations of tulathromycin, a new triamilide antibiotic, in cattle.

Marcus A Nowakowski1, Philip B Inskeep, Jim E Risk, Terry L Skogerboe, Hafid A Benchaoui, Todd R Meinert, John Sherington, Simon J Sunderland.   

Abstract

The pharmacokinetics of the new triamilide antibiotic tulathromycin was investigated in two cattle studies. Following a single subcutaneous injection, the drug was rapidly absorbed and bioavailability was excellent. High and persistent levels of the drug in lung tissue were observed as well. These attributes are advantageous for an antimicrobial drug indicated for the treatment of bacterial and mycoplasmal respiratory diseases in cattle.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15150731

Source DB:  PubMed          Journal:  Vet Ther        ISSN： 1528-3593


  22 in total

1.  Antimalarial activity of tulathromycin in a murine model of malaria.

Authors:  Nicolas Villarino; Joshua E Denny; Nathan W Schmidt
Journal:  Antimicrob Agents Chemother       Date:  2015-04-13       Impact factor: 5.191

2.  Effect of spiramycin and tulathromycin on abomasal emptying rate in milk-fed calves.

Authors:  Mehdi Rashnavadi; Mohammad Nouri; Mohammad R Haji Hajikolaei; Housain Najafzadeh; Peter D Constable
Journal:  Can J Vet Res       Date:  2014-01       Impact factor: 1.310

3.  Effects of delivery via pressure-adjustable pneumatic gas-powered dart gun of three antimicrobial drugs (ceftiofur crystalline free acid, tildopirosin, and tulathromycin) on drug disposition and meat quality in cattle.

Authors:  Thomas B Hairgrove; Virginia Fajt; Ronald Gill; Rhonda Miller; Michael Miller; Travis Mays
Journal:  PeerJ       Date:  2021-08-04       Impact factor: 2.984

4.  Concentration of the macrolide antibiotic tulathromycin in broncho-alveolar cells is influenced by comedication of rifampicin in foals.

Authors:  Monica Venner; Jette Peters; Nina Höhensteiger; Birthe Schock; Alexa Bornhorst; Markus Grube; Ulrike Adam; Eberhard Scheuch; Werner Weitschies; Dieter Rosskopf; Heyo K Kroemer; Werner Siegmund
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-12-15       Impact factor: 3.000

5.  Caprine abscess model of tulathromycin concentrations in interstitial fluid from tissue chambers inoculated with Corynebacterium pseudotuberculosis following subcutaneous or intrachamber administration.

Authors:  K E Washburn; V R Fajt; S D Lawhon; L G Adams; L A Tell; W T Bissett
Journal:  Antimicrob Agents Chemother       Date:  2013-10-07       Impact factor: 5.191

6.  Pharmacokinetics of tulathromycin in healthy and neutropenic mice challenged intranasally with lipopolysaccharide from Escherichia coli.

Authors:  N Villarino; S A Brown; T Martín-Jiménez
Journal:  Antimicrob Agents Chemother       Date:  2012-05-14       Impact factor: 5.191

7.  Comparative efficacy of enrofloxacin to that of tulathromycin for the control of bovine respiratory disease and prevalence of antimicrobial resistance in Mannheimia haemolytica in calves at high risk of developing bovine respiratory disease.

Authors:  S Crosby; B Credille; S Giguère; R Berghaus
Journal:  J Anim Sci       Date:  2018-04-14       Impact factor: 3.159

8.  Synovial fluid pharmacokinetics of tulathromycin, gamithromycin and florfenicol after a single subcutaneous dose in cattle.

Authors:  Meredyth L Jones; Kevin E Washburn; Virginia R Fajt; Somchai Rice; Johann F Coetzee
Journal:  BMC Vet Res       Date:  2015-02-07       Impact factor: 2.741

9.  Pharmacodynamics of antimicrobials against Mycoplasma mycoides mycoides small colony, the causative agent of contagious bovine pleuropneumonia.

Authors:  John D Mitchell; Quintin A McKellar; Declan J McKeever
Journal:  PLoS One       Date:  2012-08-27       Impact factor: 3.240

10.  Effect of Tulathromycin on Colonization Resistance, Antimicrobial Resistance, and Virulence of Human Gut Microbiota in Chemostats.

Authors:  Haihong Hao; Shengxi Zhou; Guyue Cheng; Menghong Dai; Xu Wang; Zhenli Liu; Yulian Wang; Zonghui Yuan
Journal:  Front Microbiol       Date:  2016-04-08       Impact factor: 5.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.